Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HI-MAP: Inpatient MDMA-Assisted Psychotherapy for PTSD
NCT06954025Phase 2Enrolling by invitation
- Sponsor
- ARQ National Psychotrauma Centre
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by ARQ National Psychotrauma Centre. Started May 2025; status: enrolling by invitation.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06954025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954025.